Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    An Enquiry

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    4-[3-chloro-4-(n'-cyclopropylureido)phenoxy]-7-methoxyquinoline-6-carboxamidemesylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 35,249Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Medivir Presenting At The Aktiespararnas Stora Aktiedagar
    Medivir Presenting At The Aktiespararnas Stora Aktiedagar

    26 Nov 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-11-26/medivir-presenting-at-the-aktiespararnas-stora-aktiedagar

    PHARMIWEB
    26 Nov 2025
    Share Share
    FDA Clears Promega OncoMate MSI As CDx For Keytruda + Lenvima
    FDA Clears Promega OncoMate MSI As CDx For Keytruda + Lenvima

    11 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251110201643/en/FDA-Approves-Promega-OncoMate-MSI-Dx-Analysis-System-as-Companion-Diagnostic-for-KEYTRUDA-in-Combination-with-LENVIMA-In-Advanced-Endometrial-Carcinoma

    BUSINESSWIRE
    11 Nov 2025
    Share Share
    Eisai Shows Dedication To Advanced Endometrial Cancer Care
    Eisai Shows Dedication To Advanced Endometrial Cancer Care

    03 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/eisai-demonstrates-commitment-to-advanced-endometrial-cancer-care-at-igcs-2025-302601410.html

    PR NEWSWIRE
    03 Nov 2025
    Share Share
    Merck, Eisai End Keytruda-Lenvima Collaboration In Liver Cancer
    Merck, Eisai End Keytruda-Lenvima Collaboration In Liver Cancer

    29 Oct 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/merck-eisai-scrap-ambitions-keytruda-lenvima-pairing-liver-cancer-subtype-after-survival

    FIERCE PHARMA
    29 Oct 2025
    Share Share
    Keytruda and Lenvima Show Long-Term Survival Benefit
    Keytruda and Lenvima Show Long-Term Survival Benefit

    18 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251018972232/en/KEYTRUDA-pembrolizumab-Plus-LENVIMA-lenvatinib-Demonstrates-Durable-5-Year-Survival-Benefit-Versus-Chemotherapy-for-Patients-With-Advanced-Endometrial-Carcinoma-Following-One-Prior-Platinum-Based-Regimen

    BUSINESSWIRE
    18 Oct 2025
    Share Share
    Eisai to Present 5-Year KEYNOTE-775 Data at ESMO 2025
    Eisai to Present 5-Year KEYNOTE-775 Data at ESMO 2025

    02 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/eisai-highlights-breadth-of-oncology-research-at-esmo-2025-featuring-5-year-survival-data-from-study-309keynote-775-302573253.html

    PR NEWSWIRE
    02 Oct 2025
    Share Share